In vitro synergism of β-lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa

被引:24
作者
Kanellakopoulou, Kyriaki [1 ]
Sarafis, Pavlos [1 ]
Galani, Irene [1 ]
Giamarellou, Helen [1 ]
Giamarellos-Bourboulis, Evangelos J. [1 ]
机构
[1] Univ Athens, Sch Med, Dept Internal Med 4, GR-11527 Athens, Greece
关键词
ceftazidime; carbapenems; ciprofloxacin; moxifloxacin; Pseudomonas aeruginosa; resistance;
D O I
10.1016/j.ijantimicag.2008.02.019
中图分类号
R51 [传染病];
学科分类号
100401 [流行病与卫生统计学];
摘要
In vitro combinations of beta-lactams with fluoroquinolones against multidrug-resistant (MDR) Pseudomonas aeruginosa were tested. From a total of 200 isolates, 24 genetically distinct isolates defined by pulsed-field gel electrophoresis (PFGE) were selected. The isolates were exposed over time to imipenem, meropenem and ceftazidime as well as to their combinations with ciprofloxacin and moxifloxacin. All isolates were resistant to all agents tested at concentrations equal to their average serum level. Synergy of any of the tested combinations was found in 10 isolates (41.7%). This was shown after 4 h and 6 h of exposure accompanied by re-growth after 24 h. Not all the tested combinations were active against the same isolates. The combinations of imipenem+ciprofloxacin, ceftazidime+ciprofloxacin and imipenem+moxifloxacin were the most active. When time-kill assays were repeated for the latter isolates at antimicrobial concentrations equal to their maximum serum levels, synergy was prolonged to 24 h. The present findings should be interpreted with caution for the management of infections by MDR P. aeruginosa. They underscore the potential interest of reporting synergism between beta-lactams and fluoroquinolones in the nosocomial setting when a MDR isolate emerges. (c) 2008 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:33 / 39
页数:7
相关论文
共 19 条
[1]
Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections [J].
Buijk, SLCE ;
Gyssens, IC ;
Mouton, JW ;
Van Vliet, A ;
Verbrugh, HA ;
Bruining, HA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (01) :121-128
[2]
In vitro evaluation of the activity of two doses of Levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa [J].
Burgess, DS ;
Hall, RG ;
Hardin, TC .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2003, 46 (02) :131-137
[3]
Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem [J].
Conte, JE ;
Golden, JA ;
Kelley, MG ;
Zurlinden, E .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 26 (06) :449-456
[4]
Should antibiotic combinations be used to treat ventilator-associated pneumonia? [J].
Eggimann, Philippe ;
Revelly, Jean-Pierre .
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 27 (01) :68-81
[5]
The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains [J].
Erdem, I ;
Kaynar-Tascioglu, J ;
Kaya, B ;
Goktas, P .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 20 (05) :384-386
[6]
Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs [J].
Fish, DN ;
Choi, MK ;
Jung, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (06) :1045-1049
[7]
Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia:: An observational, multicenter study comparing monotherapy with combination antibiotic therapy [J].
Garnacho-Montero, Jose ;
Sa-Borges, Marcio ;
Sole-Violan, Jordi ;
Barcenilla, Fernando ;
Escoresca-Ortega, Ana ;
Ochoa, Miriam ;
Cayuela, Aurelio ;
Rello, Jordi .
CRITICAL CARE MEDICINE, 2007, 35 (08) :1888-1895
[8]
Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa [J].
GiamarellosBouroulis, EJ ;
Grecka, P ;
Giamarellou, H .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1997, 29 (02) :81-86
[10]
Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers [J].
Lettieri, J ;
Vargas, R ;
Agarwal, V ;
Liu, P .
CLINICAL PHARMACOKINETICS, 2001, 40 (Suppl 1) :19-25